The use of transgenic plants as an industrial system for pharma production has many advantages over other systems. Those widely recognized are the high transformation efficiency, the low capital investment and running costs, the rapid scale-up of production and the remarkable safety due to the cancellation of the contamination risk by human pathogens such as viruses and mycoplasmas.
Exploiting the GeneHPE technology, Transactiva has started some projects aimed at the fulfillment of industrial production systems of specific drugs. Because of the increasing difficulty met by national healthcare systems in the provision at affordable costs of biopharmaceuticals, specifically those used in the therapy of rare diseases, the company has developed a platform for production of recombinant human lysosomal enzymes in the rice endosperm. Further, to meet the requirements of a personalized healthcare, Transactiva is carrying out a project of development of idiotype-specific vaccines for the therapy of non-Hodgkin lymphomas.
The expression systems set up in rice and tobacco obviously lend themselves to other applications, some of which are currently under study (e.g. production of monoclonal antibodies). Transactiva is willing to strengthen and expand relationships with large and medium-sized industries and is ready to consider proposals of development of drugs designed outside its boundaries.
Additionally, the participation to EU research projects in the field of biopharmaceutical production are welcome, particularly if they concern the control of gene expression in plants, the safety/bioequivalence of drugs produced in plants, the development of downstream processes on different plant tissues.